Reduction in tachycardia, measured through heart rate (>100 bpm) being displayed in the electronic monitors in wards, emergency room and out-patient clinics
Time frame · 6 weeks (Overall length of follow-up)
It will be assessed by trained research coordinator as; the number of study participants with 20% reduction in tachycardia as compared to the baseline between the two arms.
Improvement in mean arterial pressure, being displayed in the electronic monitors in wards, emergency room and out-patient clinics
Time frame · 6 weeks (Overall length of follow-up)
It will be assessed by trained research coordinator as; the number of study participants with 20% improvement in mean arterial pressure as compared to the baseline between the two arms.
Adverse events related to terlipressin, such as hyponatremia, diarrhea, abdominal pain; arterial hypertension should be reported to the primary gastroenterologist between the two arms.
In-patient hospital mortality, assessed through medical records.
Time frame · Admission of patient till death in the hospital
It will be assessed through medical records, by a trained research coordinator as the number of study participants dying within the hospital between the two arms.
Failure to control bleeding as assessed by physiological parameters in the blood
Time frame · Admission of patient till discharge from the hospital
It will be assessed by a trained research coordinator as the number of participants having fresh hematemesis and 3 gm drop in hemoglobin (9% drop in hematocrit) within a 24 hours' time period between the two arms.
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Time frame · 6 weeks (Overall length of follow-up)
It will be assessed by trained research coordinator as; the number of participants having experienced any adverse events such as hyponatremia, diarrhea, abdominal pain, arterial hypertension, 5 days after having terlipressin drug, between the two arms.